DR. HEINER VÖLK Pharma and Biotech Consulting | Interim Management | Coaching

is providing customized services to pharma industry, biotechnology companies and life-science investors.  These services cover executive management, business development and licensing, project management, pharmaceutical drug development, as well as market/competitive intelligence. 

Executive management, business development, licensing and competitive intelligence

• Business administration
• Strategy development and implementation
• Writing and reviewing business plans / business concepts
• Establishing new companies
• Fund raising (venture capital, grants)
• Analysing markets and competition (competitive intelligence)
• SWOT analyses
• rNPV, risk-adjusted Net Present Value determination
• Identifying co-development partners
• Business partnering & deal arranging
• Evaluating investment and licensing opportunities (compounds, portfolios or platform technologies)
• Representing customers at business conferences
• And more

Project management

• Development of manufacturing processes for biopharmaceuticals / large molecules
• Non-clinical research and development (R&D) with budget and timelines (mainly biopharmaceuticals / large molecules)
• Outsourcing (R&D performed by subcontractors)
• Drafting long-term pharmaceutical development plans (across period of 10 years)
• Drafting project plans (project management software)
• Business-to-business (B2B) technology transfers
• Translational medicine
• And more

Our services cover quite a range. For example, we provided already support for a global strategic business unit. On the other hand, we provided and are still providing allround support for several start up companies.

Some of the previous projects concerned the development and/or the business side of

• Cancer therapies
• Treatment of infectious diseases: viral (including SARS-CoV-2/COVID-19), parasitic, and bacterial
• Vaccines
• Immuno-therapies

Other previous projects concerned the development and/or the business side of

• Treatments of rare diseases
• Cell therapies
• Combined advanced therapy medicinal products (ATMP)

Divested line of previous projects

• In-vitro diagnostics (IVD)
• Companion diagnostics (CDx)